TR
EN
The efficiency and side-effects of low-dose Fludarabine-Cyclophosphamide in the treatment of chronic lymphocytic leukemia
Öz
Anahtar Kelimeler
Kaynakça
- Laurenti L, Tarnani M, De Padua L, et al. Oral fludarabine and cyclophosphamide as front-line chemotherapy in pa- tients with chronic lymphocytic leukemia. The impact of biological parameters in the response duration. Ann Hema- tol 2008;87:891-8.
- Catovsky D, Richards S, Matutes E, et al. Assessment of flu- darabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 Trial): a randomised controlled trial. Lancet 2007;370:197-8.
- Lin TS. What is the optimal initial treatment for chron- ic lymphocytic leukemia? Oncology (Williston Park) 2007;21:1641-9
- Foon KA, Boyiadzis M, Land SR, et al. Chemoimmunother- apy with low-dose fludarabine and cyclophosphamide and high dose rituximab in previously untreated patients with chronic lymphocytic leukemia. J Clin Oncol 2009;27:479- 80.
- Forconi F, Fabbri A, Lenoci M, et al. Low-dose oral flu- darabine plus cyclophosphamide in elderly patients with untreated and relapsed or refractory chronic lymphocytic Leukaemia. Hematol Oncol 2008;26:247-51.
- Fabbri A, Lenoci M, Gozzetti A, et al. Low-dose oral flu- darabine plus cyclophosphamide as first-line treatment in elderly patients with indolent non-Hodgkin lymphoma. Br J Haematol 2007;139:90-3.
- Cazin B, Divine M, Leprêtre S, et al. High efficacy with five days schedule of oral fludarabine phosphate and cyclo- phosphamide in patients with previously untreated chronic lymphocytic leukaemia. Br J Haematol 2008;143:54-9. 2008;143:54-9.
Ayrıntılar
Birincil Dil
Türkçe
Konular
-
Bölüm
-
Yayımlanma Tarihi
1 Mart 2010
Gönderilme Tarihi
27 Şubat 2015
Kabul Tarihi
-
Yayımlandığı Sayı
Yıl 2010 Cilt: 1 Sayı: 1
APA
Yokuş, O., Balcık, Ö. Ş., & Albayrak, M. (2010). The efficiency and side-effects of low-dose Fludarabine-Cyclophosphamide in the treatment of chronic lymphocytic leukemia. Journal of Clinical and Experimental Investigations, 1(1), 68-70. https://doi.org/10.5799/ahinjs.01.2010.01.0014
AMA
1.Yokuş O, Balcık ÖŞ, Albayrak M. The efficiency and side-effects of low-dose Fludarabine-Cyclophosphamide in the treatment of chronic lymphocytic leukemia. J Clin Exp Invest. 2010;1(1):68-70. doi:10.5799/ahinjs.01.2010.01.0014
Chicago
Yokuş, Osman, Özlem Şahin Balcık, ve Murat Albayrak. 2010. “The efficiency and side-effects of low-dose Fludarabine-Cyclophosphamide in the treatment of chronic lymphocytic leukemia”. Journal of Clinical and Experimental Investigations 1 (1): 68-70. https://doi.org/10.5799/ahinjs.01.2010.01.0014.
EndNote
Yokuş O, Balcık ÖŞ, Albayrak M (01 Mart 2010) The efficiency and side-effects of low-dose Fludarabine-Cyclophosphamide in the treatment of chronic lymphocytic leukemia. Journal of Clinical and Experimental Investigations 1 1 68–70.
IEEE
[1]O. Yokuş, Ö. Ş. Balcık, ve M. Albayrak, “The efficiency and side-effects of low-dose Fludarabine-Cyclophosphamide in the treatment of chronic lymphocytic leukemia”, J Clin Exp Invest, c. 1, sy 1, ss. 68–70, Mar. 2010, doi: 10.5799/ahinjs.01.2010.01.0014.
ISNAD
Yokuş, Osman - Balcık, Özlem Şahin - Albayrak, Murat. “The efficiency and side-effects of low-dose Fludarabine-Cyclophosphamide in the treatment of chronic lymphocytic leukemia”. Journal of Clinical and Experimental Investigations 1/1 (01 Mart 2010): 68-70. https://doi.org/10.5799/ahinjs.01.2010.01.0014.
JAMA
1.Yokuş O, Balcık ÖŞ, Albayrak M. The efficiency and side-effects of low-dose Fludarabine-Cyclophosphamide in the treatment of chronic lymphocytic leukemia. J Clin Exp Invest. 2010;1:68–70.
MLA
Yokuş, Osman, vd. “The efficiency and side-effects of low-dose Fludarabine-Cyclophosphamide in the treatment of chronic lymphocytic leukemia”. Journal of Clinical and Experimental Investigations, c. 1, sy 1, Mart 2010, ss. 68-70, doi:10.5799/ahinjs.01.2010.01.0014.
Vancouver
1.Osman Yokuş, Özlem Şahin Balcık, Murat Albayrak. The efficiency and side-effects of low-dose Fludarabine-Cyclophosphamide in the treatment of chronic lymphocytic leukemia. J Clin Exp Invest. 01 Mart 2010;1(1):68-70. doi:10.5799/ahinjs.01.2010.01.0014